Widely Used Joint Supplement Glucosamine Linked to Faster Dementia Progression in New Study

Widely used over-the-counter joint supplement glucosamine has been associated with a 25 percent higher likelihood of mild cognitive impairment progressing to dementia, according to new research published in Nature Metabolism. Researchers at the University of Florida analyzed extensive deidentified health records to evaluate cognitive trajectories among older adults, uncovering potential risks linked to an everyday supplement commonly consumed for joint health and aging mobility.

According to US Food and Drug Administration, under DSHEA of 1994, the US FDA regulates glucosamine as a dietary supplement rather than a drug, prohibiting pre-market efficacy approval and barring claims that it prevents or treats diseases.

The findings draw from an analysis of 41,884 individuals with mild cognitive impairment and 24,481 patients diagnosed with Alzheimer's disease and related dementias, utilizing health records collected between 2012 and 2024. After controlling for demographic variables including age and sex, the analysis linked glucosamine consumption not only to accelerated cognitive decline among patients with mild impairment, but also to a 25 percent higher mortality risk among individuals who had already developed dementia.

Investigating the Metabolic Mechanism

To explore how a joint health supplement might influence neurological health, the research team examined a biological process known as N-glycosylation, where sugar molecules attach to proteins. Postmortem human Alzheimer's brain tissue and specialized mouse models both exhibited heightened activity within this specific metabolic pathway, pointing toward a possible biological link between sugar-attachment processes and neurodegenerative disease progression.

When investigators administered oral glucosamine to mice genetically engineered to model Alzheimer's disease, the animals demonstrated elevated levels of brain N-glycans and experienced pronounced deficits during social-memory testing. Conversely, experimental procedures that suppressed glycan production enzymes improved memory performance in the animal models, providing laboratory signals that mirrored the epidemiological health-record data.

Clinical Caution and Future Trials

Study authors emphasized that while the electronic health record data reveal an association, they do not establish direct causality or prove that glucosamine triggers neurodegeneration in human patients. Study co-author Matt Gentry noted that the findings highlight an important clinical question requiring deeper investigation, particularly given how many older adults with cognitive decline independently consume over-the-counter joint supplements.

According to PubMed / Osteoarthritis and Cartilage, core clinical guidelines from OARSI designate arthritis education, structured land-based exercise regimens, and weight loss as mandatory first-line non-surgical treatments for knee and hip osteoarthritis.

Senior author Ramon Sun pointed out the significant overlap between populations seeking relief for aging joints and those experiencing cognitive impairment, warning that routine supplementation habits could inadvertently complicate disease trajectories. Researchers stressed that the preliminary results do not constitute a recommendation for patients to immediately discontinue glucosamine use, noting that definitive conclusions will require controlled human clinical trials.

Ramon Sun noted that altered metabolism contributes significantly to Alzheimer's disease progression, indicating that correcting this defect might complement strategies targeting plaques and tangles. To account for Alzheimer's disease-related risk factors, the study used propensity score matching with a one-nearest-neighbour algorithm to balance covariates.

Next Steps in Neurological Research

With publication in Nature Metabolism bringing renewed attention to the metabolic underpinnings of cognitive decline, the academic team maintains that observational datasets must be validated through rigorous prospective trials. Further clinical evaluation remains necessary to determine whether the observed statistical associations reflect a direct pathological effect of glucosamine on human neurological function.